Polymarket · Tech & ScienceClosed
Loading the chart…
| Outcome | Chance | 24h | 1 week | Bid · Ask | 24h volume | Ends |
|---|---|---|---|---|---|---|
| Yes | 100% | +27 pts | — | >99¢ · 100¢ (<1¢) | — | ended |
| When | Trader | Outcome | Bet | Size | P&L now | Insider |
|---|---|---|---|---|---|---|
| 501d | FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)? | BuyYes>99¢ | $5,257 | +$15 +0.3% | 4 | |
| 501d | FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)? | BuyYes>99¢ | $1,727 | +$3 +0.2% | 4 | |
| 501d | Wonfo | FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)? | BuyYes>99¢ | $1,011 | +$2 +0.2% | 4 |
| 501d | FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)? | BuyYes>99¢ | $2,809 | +$8 +0.3% | 4 | |
| 501d | SweetChariot | FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)? | BuyYes>99¢ | $1,145 | +$5 +0.4% | 4 |
| 501d | FDA approves Merck’s clesrovimab infant RSV prevention (MK‑1654)? | BuyYes89¢ → 100¢ | $2,208 | +$273 +12% | 4 |
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Merck’s biologics license application (BLA) for clesrovimab (MK‑1654) as a preventive treatment for respiratory syncytial virus (RSV) in infants by June 17, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No". This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL), explicitly declines to approve the application. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA, however a consensus of credible reporting may also be used.
Sources: Polymarket's Gamma API, its CLOB price history and its Data API, read every two minutes. Prices are each outcome's Yes price, which is the market's probability: 100¢ for Yes means the market gives it about 100%.